Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $106.78M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.02M
Average 0.04M
CLLS Total Liabilities
Everything the company owes to creditors and other parties.
Cellectis S.A.NASDAQ: CLLS
Total Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total liabilities falls 7.5% from a year ago
Total liabilities stood at $229.27M at the end of Q1 FY2026, down 7.5% from a year earlier and down 7.9% from the prior quarter. Over 3 fiscal years it compounded at +22.5% a year.
Context
- Total liabilities amounted to 79.3% of total assets at the end of Q1 FY2026, up 11.2 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps falling in the next quarterly balance sheet after a -7.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 248.82M USD
- Year-over-year change
- -1.5%
- 4-year CAGR
- +14.3%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 248.82M | -1.5% |
| FY2024 | 2024-12-31 | 252.51M | +1.2% |
| FY2023 | 2023-12-31 | 249.58M | +84.5% |
| FY2022 | 2022-12-31 | 135.28M | -7.1% |
| FY2021 | 2021-12-31 | 145.6M | — |
Total Liabilities vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so total liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -7.5% is the 7th highest of 11, against a peer median of +0.7%.
- Total liabilities amounts to 79.3% of total assets for CLLS, versus a peer median of 32.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $229.27M USD | -7.5% | +22.5% | 79.3% | |
| Mar 2026 | $196.35M USD | +7.9% | -10.1% | 30.4% | |
| Mar 2026 | CHF 105.89M CHF | -8.9% | +86.2% | 77.1% | |
| Mar 2026 | $65.72M USD | -77.9% | -6.8% | 57.1% | |
| Mar 2026 | $63.99M USD | +1.2% | -28.9% | 34.8% | |
| Mar 2026 | $58.5M USD | +22.7% | +7.6% | 22.0% | |
| Mar 2026 | $50.48M USD | +94.9% | +63.5% | 24.2% | |
| Mar 2026 | $39.42M USD | +60.2% | +26.7% | 36.2% | |
| Mar 2026 | $32.89M USD | +0.2% | -27.8% | 11.9% | |
| Mar 2026 | $24.33M USD | -17.8% | -2.8% | 36.6% | |
| Mar 2026 | $6.56M USD | -20.4% | -42.3% | 16.2% | |
| Peer median (excluding CLLS) | — | +0.7% | -4.8% | 32.6% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 185.64M | 89.79M | 136.71M | 143.25M | 63.58M |
| Short-term Investments | 499K | 7.91M | 67.11M | 117.06M | 145.08M |
| Net Receivables | 31.07M | 17.57M | 23.13M | 23.04M | 25.32M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 50K | 22.31M | 345K | 298K | 329K |
| Total Current Assets | 225.43M | 143.81M | 233.01M | 287.07M | 236.24M |
| Property, Plant & Equipment (Net) | 148.27M | 107.9M | 92.74M | 75.86M | 62.45M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 1.85M | 718K | 672K | 1.12M | 535K |
| Long-term Investments | 6.52M | 8.79M | 7.85M | 7.52M | 5.09M |
| Tax Assets | 0 | 0 | 0 | 382K | 382K |
| Other Non-current Assets | 3K | 0 | (1K) | 11.6M | 20.03M |
| Total Non-current Assets | 156.65M | 117.41M | 101.27M | 96.48M | 88.48M |
| Total Assets | 382.08M | 261.22M | 334.27M | 383.54M | 324.72M |
| Account Payables | 23.76M | 21.46M | 19.07M | 18.66M | 17.28M |
| Short-term Debt | 2.25M | 4.97M | 5.16M | 4.84M | 18.16M |
| Tax Payables | 71K | 3.06M | 0 | 16K | 0 |
| Deferred Revenue | 301K | 59K | 110.33M | 112.16M | 96.8M |
| Other Current Liabilities | 2.16M | 16.16M | 2.72M | 13.37M | 13.51M |
| Total Current Liabilities | 49.35M | 63M | 155.14M | 166.27M | 145.75M |
| Long-term Debt | 18.77M | 13.57M | 28.44M | 43.99M | 74.01M |
| Deferred Tax Liabilities | 0 | 0 | 158K | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.96M | 9.35M | 22.88M | 17.02M | 1.33M |
| Total Non-current Liabilities | 96.25M | 72.28M | 94.43M | 95.25M | 103.07M |
| Total Liabilities | 145.6M | 135.28M | 249.58M | 252.51M | 248.82M |
| Common Stock | 2.95M | 2.96M | 4.37M | 5.89M | 5.9M |
| Retained Earnings | (698.33M) | (439.5M) | (405.77M) | (329.61M) | (334.13M) |
| Accumulated OCI | (18.02M) | (28.61M) | (36.69M) | (39.54M) | (33.32M) |
| Other Stockholders Equity | (1K) | 0 | 1K | 0 | 0 |
| Minority Interest | 15.18M | 7.97M | 0 | 0 | 0 |
| Total Equity | 236.47M | 125.94M | 84.7M | 131.03M | 75.9M |
| Total Debt | 100.87M | 75.77M | 85.06M | 91.46M | 119.9M |
| Net Debt | (84.77M) | (14.02M) | (51.65M) | (51.79M) | 56.32M |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.06
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.